NCT01626859

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia (12 Weeks Treatment Study)

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Tanabe Pharma Corporation · Industry
• Sex: All
• Age: 20 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	MP-214 3mg	Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.
DRUG	MP-214 6mg	Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.
DRUG	MP-214 9mg	Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.

Timeline

• Start date: 2012-05-01
• Primary completion: 2013-08-01
• Completion: 2013-08-01
• First posted: 2012-06-25
• Last updated: 2026-01-05
• Results posted: 2021-04-12

Locations

1 site across 1 country: Japan